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Abstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the
treatment of HIV-1 infection brings promise of a new mode of delivery and potential
solutions to some problems of oral therapy, but also new challenges and unanswered
questions. Adding to the increasing body of evidence for newer two-drug combinations,
phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination
injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most impor-
tantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-
weekly injections, despite frequent injection-site reactions. Key outstanding questions
include management of missed or delayed dosing, drug interactions and management of
virological failure, as well as the efﬁcacy of cabotegravir and rilpivirine in all HIV-1
subtypes. We describe clinical evidence to date and efﬁcacy and challenges in selected
populations, including women; those with prior virological failure; individuals with a history
of difﬁculty adhering to oral therapy and individuals with co-infections. We await real-world
data and longer-term evidence while moving forward to this new era of antiretroviral
therapy.
Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase
inhibitors
Introduction
The global response to HIV (human immunodeﬁciency virus) has meant more
people living with HIV (PLWH) are diagnosed, on treatment and living
longer than ever before.1 But there still remain several unmet needs in HIV
treatment across the globe, including more tolerable treatments, easier to
adhere to, and, stemming from the UNAIDS 90-90-90 targets,2 addressing
the “4th 90”: improvement of quality of life in those living and aging with
HIV.3,4
Long-acting (LA) injectable therapy offers much-reduced dosing frequency and
an additional option among two-drug combinations now available. Delivery of LA
injectable antiretroviral therapy (ART) may require a conformational change in
HIV healthcare delivery for some, with possibilities for more innovative, patient-
centered health care models.
Pre-clinical data on LA cabotegravir and detail on rilpivirine pharmacoki-
netics have been described previously.5,6 Here, we describe phase II and III
clinical trials, discuss resistance and suitability for speciﬁc populations.
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Drug characteristics
Cabotegravir (GSK1265744) is an integrase strand transfer
inhibitor (INSTI) of the carbamoyl pyridone class and a
structural analog of dolutegravir. At the time of writing,
cabotegravir is still an investigational antiretroviral agent,
manufactured as a once-daily oral tablet and as an intra-
muscular (IM) and subcutaneous (SC) injectable. Not yet
licensed, it is available, in Europe, through the manufac-
turer’s expanded access program.7 Cabotegravir is formu-
lated as an LA suspension for monthly to quarterly
injection dosing.8 The half-life (t1/2) of LA injectable
cabotegravir is 20–40 days with some individuals having
measurable concentrations cabotegravir up to a year after
one single dose.8,9
Rilpivirine (TMC278) is a second-generation non-
nucleoside reverse transcriptase inhibitor (NNRTI),
licensed for the treatment of HIV-1 infection in individuals
aged ≥12 years with plasma HIV-1 RNA (ribonucleic acid)
≤100,000 copies/mL,10,11 based on the ECHO and
THRIVE studies.12,13 It is licensed as a 25 mg oral tablet
and in co-formulation as single tablet regimens with dual
nucleoside reverse transcriptase inhibitors (NRTIs) and
with dolutegravir.14–16 An LA injectable suspension has
been developed for use with cabotegravir as injectable
ART and, like cabotegravir, is available through an
expanded access program.17 The t1/2 of LA rilpivirine is
30–90 days.18–20
Oral rilpivirine needs to be taken with a meal for
optimal absorption and cannot be co-administered with
proton-pump inhibitors.21 Frequently occurring side
effects (SE) are headaches, insomnia, dizziness and nau-
sea, increases in total and low-density lipoprotein choles-
terol, rises in pancreatic amylase and derangement of
transaminases.22 Data on cabotegravir side effects to date
come from trials and are discussed later.
Healthy volunteer studies of oral rilpivirine given with
dolutegravir or cabotegravir demonstrate no signiﬁcant
pharmacokinetic interactions, no requirement to dose-
adjust either drug and a favorable short-term safety
proﬁle.23 To date, there are two key phase II and two
phase III clinical trials that support the efﬁcacy and safety
of oral and injectable cabotegravir with rilpivirine (CR);
LATTE and LATTE-2, ATLAS and FLAIR.
Clinical trial evidence
Phase II studies
The Long-Acting antireTroviral Treatment Enabling trial
(LATTE) is a phase IIb randomized, partially blinded,
dose-ranging study of once-daily oral CR, which has
now reported 96-week results.24 It compared three dose-
ranging CR arms with two NRTIs plus efavirenz
(Figure 1).
LATTE recruited ART-naïve HIV-1 positive adults (age
≥18 years) with no major resistance-associated mutations
(RAMs) at baseline. Investigators and participants were
blinded only to the cabotegravir dose. As shown in
Figure 1, at week 24, participants switched from the induc-
tion to maintenance phase. Participants in arms 1–3 only
continued to the maintenance phase if HIV-1 RNAwas <50
copies/mL, but those in arm 4 continued the same oral
efavirenz-based regimen regardless of viral load (VL).
Resistance testing was done at baseline and protocol-deﬁned
virological failure (PDVF). Randomization was stratiﬁed by
baseline HIV-1 VL (< or ≥100,000 copies/mL) and by NRTI
backbone (abacavir-lamivudine or tenofovir-emtricitabine).
Induction 
phase
Maintenance 
phase
CAB 10mg
+ 2 NRTIs CAB 10mg + RPV 25mg
CAB 30mg
+ 2 NRTIs
CAB 60mg
+ 2 NRTIs
CAB 30mg + RPV 25mg
CAB 60mg + RPV 25mg
EFV 600mg + 2 NRTIs
Week 24
ART naïve
Age ≥18
No major RAMS
Week 96
Figure 1 The Long-Acting antireTroviral Treatment Enabling trial (LATTE).
Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir; RPV, rilpivirine; EFV, efavirenz; NRTis, nucleos(t)ide reverse transcriptase inhibitors; RAMS, resistance-associated
mutations.
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The primary end point was an intention-to-treat (ITT)
analysis in the exposed population of the proportion of
participants with HIV-1 RNA<50 copies/mL at week 48.
Of 243 patients enrolled and receiving at least one dose of
an oral induction regimen, 207 patients took at least one
dose of the oral maintenance regimen. At week 48, the
combined overall response (HIV-1 VL<50 copies/mL) in
the CR arms was 82% versus 71% in the 2-NRTI and
efavirenz arm. This difference in virological suppression
was seen through to week 96 (combined 76% for CR vs
63% for 2-NRTI and efavirenz). In all CR regimens
(regardless of cabotegravir dose), there were fewer parti-
cipants with baseline HIV-RNA≥100,000 copies/mL who
sustained virological suppression at week 96 than with
lower VLs. However, the authors concluded that numbers
were too small to draw signiﬁcant conclusions from this.
An efﬁcacy analysis of the ITT maintenance-exposed
population found numerical superiority of cabotegravir
60 mg and 30 mg in achieving viral suppression at week
96 compared with 10 mg.
Overall, the CR regimens had better tolerability, fewer
adverse event (AE)-related discontinuations and a lower
proportion with virological non-response. In the cabotegra-
vir arms, there was a higher frequency of headaches,
depression and vomiting (22%, 11% and 8% of the partici-
pants on cabotegravir versus 8%, 6% and 5% on efavirenz).
Two participants taking cabotegravir 60 mg had increasing
transaminases on a background of steatohepatitis that
improved on drug discontinuation. Dizziness, abnormal
dreams, nausea, fatigue and insomnia were, as expected,
the most frequent AEs in the NRTI and efavirenz arm. The
30 mg cabotegravir dose was taken forward for assessment
as LA injectable.
LATTE-2 is a phase IIb, randomized, open-label, non-
inferiority study of LA CR, aiming to select a dosing
regimen.25 It recruited ART-naïve HIV-1 positive adults
(aged ≥18 years) with CD4 counts≥200 cells/µL and HIV-
1 VL≥1000 copies/mL. As depicted in Figure 2, partici-
pants had a 20-week oral induction phase of cabotegravir
30 mg plus abacavir–lamivudine, with oral rilpivirine
added at week -4 (16 weeks into induction phase). Those
with HIV-1 RNA<50 copies/mL at week -4 were rando-
mized to one of the three maintenance treatment arms: LA
cabotegravir 400 mg plus rilpivirine 600 mg every 4
weeks (q4w); LA cabotegravir 600 mg plus rilpivirine
900 mg every 8 weeks (q8w) or oral cabotegravir 30 mg
plus abacavir-lamivudine daily. The study allowed a 14-
day window for injections to more closely resemble real-
world settings.
The primary outcomes were the proportion of the
maintenance-exposed population with HIV-1 RNA <50
copies/mL at week 32 of the maintenance period, propor-
tion with PDVF and the incidence and severity of AEs and
laboratory abnormalities. The extended analysis continued
to 160 weeks, with those randomized to oral cabotegravir
30 mg plus abacavir-lamivudine and virologically sup-
pressed at 96 weeks switching to LA CR at 100 weeks,
with optimized loading doses (cabotegravir 600 mg and
rilpivirine 900 mg) then q4w or q8w regimens.26
Of 309 participants, 21 (7%) withdrew during the
induction period. Among these, ﬁve stopped due to lack
of efﬁcacy, three for liver events according to pre-speciﬁed
Induction 
phase
Maintenance phase
(commenced if HIV-1 VL<50 copies/mL at week -4)
LA CAB 400mg + LA RPV 600mg Q4W
PO CAB 30mg
+ ABC/3TC LA CAB 600mg + LA RPV 900mg Q8W
PO CAB 30mg + ABC/3TC
Week 0
ART naïve
Age ≥18
CD4 count ≥ 200
HIV-1 VL>1000 
Week 96Week-20 Week-4:
Add RPV 25mg
Extension 
phase
Extension 
phase
Extension 
phase
Week 
160
Figure 2 The Long-Acting antireTroviral Treatment Enabling trial - 2 (LATTE-2).
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeﬁciency virus; ABC, abacavir; 3TC, lamivudine; CAB, cabotegravir; RPV, rilpivirine; Q4W, every 4 weeks;
QSW, every 8 weeks; LA, long-acting; PO, oral.
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criteria and three for other AEs. During the maintenance
period, 28/286 (10%) participants had withdrawn by week
96. Ten withdrew due to AEs, of which eight were in the
q4w injectable arm.
There was comparable virological suppression between
both injectable arms and the oral treatment arm at week 32,
also seen at weeks 48 and 96 (Table 1). Among three with
PDVF, one patient in the q8w arm had treatment-emergent
resistance after 4 weeks with reverse transcriptase (RT)
mutations K103N, E138G and K238T conferring low-
level resistance to rilpivirine, and Q148R mutation confer-
ring high-level resistance to raltegravir, elvitegravir and
cabotegravir, but lower-level resistance to dolutegravir
and bictegravir. In a second participant in the q8w arm,
the mixture R269R/G was detected at week 48; mutations
at codon 269 are not known to decrease cabotegravir
susceptibility.27
Injection site reactions (ISRs) were the most common
AE reported in both injectable arms. Pain occurred in
>95% of all patients and nodules and swelling in >25%.
Most ISRs were mild and short-lived (median 5 days). ISR
frequency decreased from day 1 (≥85% in both arms) to
approximately half this at week 4. Headaches were com-
mon, in up to 25% in all arms, although these were mostly
mild and not treatment-related.
At week 48, all arms achieved mean trough concentra-
tions greater than the in vitro protein-adjusted 90% inhi-
bitory concentration for cabotegravir and rilpivirine
against HIV-1 wild type (0.166 µg/mL and 12 ng/mL,
respectively). Based on the results of LATTE-2, an opti-
mized q4w dosing regimen for a future phase III study was
selected, although both q4w and q8w schedules are under-
going further evaluation. In an extension to 160 weeks,
enrolled participants in the injectable arms continued on
their current treatment regimen and those on the oral arm
who were virologically suppressed were switched to
receive an optimized loading dose followed by the q4w
or q8w injectable regimen. At week 160, both IM LA
regimens have continued to maintain virological control
and no patients have experienced protocol-deﬁned virolo-
gical failure after week 48.26
Phase III studies
Two phase III trials have now reported 48-week data as
conference presentations, both showing LA CR to be non-
inferior to continued oral triple therapy in terms of the
proportion of participants with viremia at that time.28,29
FLAIR is an ongoing open-label study enrolling ART-
naïve, hepatitis B surface antigen negative individuals, with
no NNRTI RAMs other than K103N (Figure 3). Baseline
integrase resistance testing was not done, consistent with cur-
rent international clinical practice for ART-naïve individuals.
On enrolment, all commenced a 20-week induction phase of
the oral ﬁxed-dose combination abacavir, lamivudine and
dolutegravir. At week 20, those with HIV RNA <50 copies/
mL asmeasured at week 16 proceeded to randomization 1:1 to
either continue this oral therapy or to switch to a 4-week oral
lead-in of CR. After this 4-week period, a loading dose of LA
cabotegravir 600 mg and rilpivirine 900 mgwas administered,
followed by q4w maintenance doses of IM LA cabotegravir
400 mg and rilpivirine 600 mg.
The primary endpoint was proportion with HIV RNA
>50 copies/mL at 48 weeks (ie, 44 weeks after starting
injectable therapy), using the required FDA “snapshot”
algorithm. Secondary outcomes included resistance at con-
ﬁrmed virological failure, safety and tolerability and
patient-reported outcomes. The trial recruited (ITT popu-
lation) 566 individuals, with 283 in each arm.
For the primary outcome of proportion viremic at 48
weeks (HIV RNA>50 copies/mL), 2.1% (6/283) in the LA
arm and 2.5% (7/283) in oral arm were viremic, showing
non-inferiority of LA versus oral triple therapy. There were
four (1.4%) individuals in the LA treatment arm who dis-
continued due to lack of efﬁcacy and three (1.1%) in the oral
treatment arm. There were three participants with con-
ﬁrmed virological failure in the LA treatment arm. Detail
available to date on these showed that all three were from
Russian study sites and all infected with type A1 virus. At
the time of virological failure, one had the NNRTI RAM
E138K, one had the mixture E138E/A/K/T and one K101E.
Integrase mutation Q148R was found in two, G140R in one
and all showed the integrase polymorphism L74I. However,
on testing baseline HIV RNA, the L74I was present in all
before treatment start. Alone, L74I does not affect INSTI
susceptibility, although it contributes to resistance when
found with other mutations, including at position 148.27
Drug levels in these three individuals were within the
range of those who were virologically suppressed, indicat-
ing that injections had been administered and that subther-
apeutic levels alone do not explain the failure. Data on the
baseline mutations and polymorphisms among those who
remained virologically suppressed are needed to compare
and we await further information to understand the signiﬁ-
cance of these descriptive data.
Fernandez and van Halsema Dovepress
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As in LATTE-2, the most common AEwas ISR, decreas-
ing in severity and frequency over time. Two participants
withdrew from the LA arm because of ISRs, but the majority
were non-severe and self-limiting. Participants again
reported high levels of satisfaction with the LA treatment.28
ATLAS is a phase III, open-label, randomized study
recruiting virologically suppressed participants, stable for
at least six months on an oral regimen of two NRTIs plus a
third agent (protease inhibitor (PI), NNRTI or INSTI).29,30
Of note, those on ﬁxed-dose combination abacavir, lami-
vudine and dolutegravir were excluded and a reason for
this is not given. Also excluded were individuals with a
prior switch due to treatment failure (HIV-1 RNA≥400
copies/mL), those who have had over one-month break
from ART and those with clinically signiﬁcant comorbid-
ities. This may limit generalizability outside of these
groups. Participants with the RT mutation K103N were
not excluded. Participants were randomized 1:1 to con-
tinue their oral regimen or switch to a 4-week oral lead in
phase of daily CR, then proceed to a loading dose and q4w
maintenance LA CR, with the same regimens as used in
FLAIR. Data for the 48-week primary endpoint have been
presented, but the study is ongoing, including an extension
phase of the same q4w regimen and a study of the q8w
regimen, “ATLAS 2M”.
Median prior duration of ART was 4 years, ranging
from 1 to 21 years. The third agent was an NNRTI in 50%.
At week 48, 1.6% (5/308 participants) in the LA arm and
1.0% (3/308) in the oral arm had virological nonresponse,
with HIV RNA ≥50 copies/mL. The adjusted treatment
difference met the deﬁnition of non-inferiority. Virological
success was seen in 92.5% (285/308) participants in the
LA therapy arm, compared with 95.5% (294/308) in the
oral therapy arm.
As seen in FLAIR, there was some resistance emerging at
failure in the LA therapy arm and further study on this is
warranted. To date, we know that two were from Russian and
one from a French study site; all had subtype A viruses (two
A/A1 in Russia, one AG in France). RNA-based resistance
testing at failure showed the RT mutation E138A, E or K,
associated with rilpivirine resistance, in all three, with V108I
in one. On integrase testing, L74I was seen in two, of whom
one also had N155H, associated with a 2.7-fold change in
susceptibility to cabotegravir. As in FLAIR, drug levels were
below mean for the study population, but within range for
most participants who maintained virological suppression.
Comparing with baseline DNA (deoxyribonucleic acid)
resistance testing (undertaken on stored samples, since all
participants had HIV RNA<50 at baseline), E138 mutations
were seen in two participants in baseline samples and L74I in
two. Data on baseline DNA mutations among those with
virological suppression at 48 weeks are not yet available
and we should interpret DNA resistance testing with caution
since it is not widely used in clinical practice andmay include
LA CAB 400mg + LA RPV 900mg 
Q4W
Week 24
Induction 
phase
Maintenance phase
(commenced if HIV-1 VL<50 copies/mL at week 16)
PO CBV + 
RPVPO DTG
+ ABC/3TC
PO DTG + ABC/3TC
Week 20
ART naïve
Age ≥18
Week 48
FLAIR
LA CAB 400mg + LA RPV 900mg Q4W
Continuation of PO ART
6 months uninterrupted ART
Age ≥18
VL<50 copies/mL
Week 48ATLAS
PO CBV 
+ RPV
Extension 
ATLAS 2M
Extension 
ATLAS 2M
Week 4
Figure 3 FLAIR and ATLAS.
Abbreviations: ABC, abacavir; 3TC, lamivudine; CAB, cabotegravir; RPV, rilpivirine; OTG, dolutegravir; ART, antiretroviral therapy; Q4W, every 4 weeks; LA, long-acting;
PO, oral.
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non-replicative viral DNA31 although resistance in viral
DNA has been associated with future virological failure in
some individuals.32
AEs were similar to those seen in FLAIR, with more
drug-related AEs in the LA treatment arm (as would be
expected in a study in which participants stable for six
months on an oral regimen are randomized to switch) and
headache reported by 11% in the LA treatment arm, versus
6% in the oral therapy arm. Only 10 participants in the LA
treatment arm and 5 in the oral therapy arm withdrew due
to AEs. Again, ISRs occurred and decreased in frequency
as the study progressed and 99% were grade 1–2. There
were few discontinuations due to ISRs and again those
switching to injectable therapy expressed high levels of
satisfaction with the treatment.
Participant satisfaction and qualitative data:
“it might be painful, but it is better than
pills”33
The HIV Treatment Satisfaction Questionnaire (HIVTSQ)
is a 10-item validated questionnaire developed to evaluate
HIV therapy. It addresses issues such as perceived conve-
nience, ﬂexibility and understanding of treatment as well
as whether PLWH would be satisﬁed to continue their
current form of treatment or would recommend it to
others. The original status version (HIVTSQs) has since
been updated to the new change version (HIVTSQc) that
better allows tracking of change in satisfaction, but both
are validated for use in clinical trials.34,35 A 12-item
HIVTSQ (HIVTSQ-12) has now been created to address
the discomfort caused by therapy and its ease of use.36
In LATTE-2, the HIVTSQ was used to assess partici-
pant satisfaction with injectable versus ongoing oral treat-
ment. High levels of satisfaction were recorded, with 98%
and 99% of the participants in injectable arms reporting
that they were satisﬁed or very satisﬁed to continue at
week 48, compared with 88% in the oral arm. This is
despite ISRs, although of course in a preselected popula-
tion who agreed to randomization to injectable therapy.25
A separately published qualitative study of LATTE-2
participants in the US and Spain provided in-depth interview
data from 27 participants (including only two females) and
12 providers.33 Key conclusions were that participants
reported convenience of LA injections and beneﬁted from
the emotional advantage of reduced risk of inadvertent dis-
closure and eliminating the daily reminder of living with
HIV. Beneﬁts in terms of stigma and discrimination were
cited, with reduced concern about travel to countries where
laws still discriminate on the basis of HIV status.
However, participants did express concern regarding
the increased frequency of clinic visits, with colleagues
noticing time off, and many hoped for less frequent injec-
tions to be available. Participant views were largely posi-
tive, albeit among those choosing to participate in the trial,
experiencing virological suppression on LA therapy and
then agreeing to participate in a qualitative sub-study.
Providers of injectable therapy were not so selected
and had some concerns about the characteristics of
PLWH who would most beneﬁt from injectables and the
fact that injectable therapy does not completely obviate the
need for adherence to a medication schedule. Other con-
cerns included emergent resistance if injections are missed
and issues with switching if necessitated by new conco-
mitant medications.
ATLAS and FLAIR have also used the HIVTSQ to
determine participant satisfaction with injectable therapy
with participants in both studies demonstrating markedly
higher levels of satisfaction with LA regimens compared
to oral therapy. In those participants who switched from
oral to injectable therapy in both studies, the vast majority
of responding participants (99% in FLAIR and 97% in
ATLAS) preferred injectable therapy.28,29
Drug tolerability
LA injectable therapy is presumed advantageous to oral
therapy in part because of better tolerability, higher patient
satisfaction and reduced need for daily adherence.
Rilpivirine has a favorable safety proﬁle compared to older
NRTIs, with lower rates of AEs and discontinuations com-
pared to efavirenz in its licensing studies.12,13 The most
frequent AE reported with injectable cabotegravir for both
treatment and pre-exposure prophylaxis is mild ISR.25,37,38
Despite LATTE detecting a higher frequency of headaches
and depression in participants on oral cabotegravir versus
efavirenz, only headaches were reported to be treatment-
related and at a frequency of >10%24 with only 5–6% of the
patients in LATTE-2 suffering treatment-related
headaches.25 Other potential neurocognitive side-effects
(depression, memory impairment, asthenia and myalgia,
and anxiety) were observed in the cabotegravir group in
ATLAS causing treatment discontinuation but were not
felt to be drug-related.29 The neurocognitive AEs seen
with dolutegravir post-licensing have not, to date, been
reported with cabotegravir.39–43
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Weight gain has now been reported as a potential
complication of INSTI use,.44 To date, pre-exposure pro-
phylaxis (PrEP) studies have found no increase in weight
gain with cabotegravir compared to placebo,45 but further
data on this are needed from treatment studies.
Drug resistance in in vitro and in vivo
studies
Two key aspects to consider are: ﬁrst, the suitability of CR
LA therapy for individuals with pre-existing RAMs or with
experience of several ART regimens before moving to long-
acting injectables; second, the frequency and nature of resis-
tance emerging on treatment and a consideration of what
treatment combinations may be effective after failure.
In the licensing studies for rilpivirine, ECHO and
THRIVE,12,13 and similarly in the STAR study,46 treat-
ment-naïve adults with any of 39 NNRTI mutations at
baseline were excluded, including K103H/N/S/T, which
was appropriate since the comparator arm was an efavir-
enz-based regimen. Similarly, in the studies of oral dolute-
gravir and rilpivirine, SWORD-1 and SWORD-2,47 in
which individuals who were stable on ART were rando-
mized to switch to the dual therapy or continue triple
therapy, exclusion criteria included any previous switch
because of virological failure and evidence of major muta-
tions associated with resistance to PI, INSTI, NRTI or
NNRTI groups. This limits the generalizability of the
data to more treatment-experienced individuals, particu-
larly those with long treatment histories including the
ﬁrst-generation NNRTIs or dual NRTI therapy. The
WISARD study, now recruiting, will investigate the efﬁ-
cacy of dolutegravir and rilpivirine dual therapy among
individuals with the K103N mutation and should provide
useful data for that oral regimen.48 However, we must be
cautious in extrapolating results of dolutegravir-based stu-
dies to cabotegravir, since they are not identical, particu-
larly in terms of resistance proﬁle. Both LATTE studies
also excluded individuals with major RAMs.
In terms of treatment-emergent resistance, we await
further data on those experiencing virological failure in
ATLAS and FLAIR. We note that in the rilpivirine licen-
sing studies the most frequent emerging rilpivirine-asso-
ciated RAM was E138K.49 Considering potential
treatment after virological failure on CR, individualized
regimens would have to be constructed depending on
RAMs found and susceptibility to agents with high genetic
barrier to resistance.
In vitro studies may indicate potential for the develop-
ment of resistance to cabotegravir following virological
failure on ﬁrst-generation INSTIs, with novel mutations
C56S and G149A occurring on passage of Q148H virus
(indicating resistance to raltegravir and elvitegravir) in the
presence of cabotegravir.50 In vitro activity of cabotegravir
against HIV-1 isolates with mutations affecting raltegravir
and elvitegravir appears lower than that of dolutegravir
and bictegravir, particularly against raltegravir-resistant
isolates with G140S or Q148H.51 Cabotegravir is consis-
tently shown to be less potent than bictegravir and dolute-
gravir in vitro, with the Q148R/K seen in clinical trials
resulting in cross-resistance across the INSTI class.52
Therapeutic potential in differing
patient populations
ART-experienced patients or with
advanced HIV infection (CD4≤200)
Both LATTE and LATTE-2 excluded treatment-experi-
enced individuals, those with major RAMs and those
with active complications from late-stage HIV.24,25
Enrolled participants had relatively high median CD4
counts in both studies, as individuals with baseline CD4
counts<200 cells/µL were excluded. In LATTE, across CR
arms there were lower proportions with baseline HIV-1
RNA≥100,000 copies/mL versus <100,000 that achieved
virological suppression at week 96, but numbers in each
group were small.24 Therefore, the use of injectable CR in
ART-experienced individuals or those with low CD4
counts is yet to be evidenced.
LATTE-2 included a sub-study that analyzed paired
plasma and cerebrospinal ﬂuid (CSF) taken seven days
after an LA CR dose (15 participants receiving cabotegravir
q8w and three receiving cabotegravir q4w). CSF cabotegra-
vir concentrations positively correlated with total plasma
cabotegravir concentrations. Both cabotegravir and rilpivir-
ine concentrations exceeded their in vitro 50% inhibitory
concentration (IC50) for wild-type HIV-1 in all but one
patient with a CSF rilpivirine concentration of <1 ng/mL
(rilpivirine IC50 0.081 ng/mL). All patients maintained high
rates of virological suppression in plasma and CSF with only
one patient in the q8w arm having detectable CSF HIV RNA
on the SuperLow assay (detects HIV-1 RNA>2 cells/mL) but
undetectable on the Abbott real-time assay (HIV-1 RNA<50
cells/mL).53 Thus, cabotegravir and rilpivirine seem to effec-
tively penetrate the CSF and are able to successfully sup-
press HIV replication in this sanctuary site making it a
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suitable regimen for those with advanced infection and pos-
sible or deﬁnite CNS opportunistic infections (OIs).
Individuals with no enteral route
At present only the fusion inhibitor enfuvirtide (T20) and
the NRTI zidovudine are available in injectable form and
neither are feasible now for maintenance therapy. LA
injectables may provide a much-needed option for the
few individuals with poor gastrointestinal absorption due
to severe illness, swallowing problems or comorbidities
although its data on its use in this context will probably
only be available post-marketing.
Individuals with suboptimal adherence to
oral therapy
The potential beneﬁt to this group is yet to be demon-
strated in studies, but the potential to maintain virological
suppression where oral therapy has not would of course be
beneﬁcial. In some with chaotic lifestyles or addictions,
LA injectables may not be the answer. Concerns include
missing or delayed injections, causing reduction in blood
levels of drug to below those required for virological
suppression and leading to resistance that threatens future
options. Strategies such as oral CR or other drugs, for
example, PIs, to cover this pharmacokinetic “tail” are not
yet evidenced but are needed. For those individuals for
whom daily oral therapy presents a psychological burden,
but who maintain engagement with clinical care, LA
injectables could present a solution. However, studies to
date have all used an oral lead-in period and starting
injectable therapy without this, or in a true ART-naïve
population, is not yet evidenced. There is still a knowledge
gap in the efﬁcacy of LA therapy in patients with prior
treatment-failure or those with treatment breaks as they
have been excluded from trials.30
Individuals requiring NRTI-sparing
regimens
Despite the appeal of two-drug regimens, not all combina-
tions are equally efﬁcacious or non-inferior to triple-drug
combinations, and some may cause use-limiting toxicity.54
CR has the advantage of avoiding long-term toxicity of
NRTIs and the toxicity and drug interactions of PIs.55,56
LA CR is a tenofovir disoproxil (TDF)-sparing regimen
that reduces pill burden and eliminates the renal and bone
risks associated with long-term TDF use. However, the
role of tenofovir-sparing regimens with the availability
now of tenofovir alafenamide (TAF) is less clear.
Individuals with co-infections and
comorbidities
Most participants in LATTE and LATTE-2 had no signiﬁ-
cant comorbidities. Both studies included a small number
of hepatitis C RNA positive individuals, although hepatitis
B infection was an exclusion criterion in both because of
the tenofovir-free regimens.24,25 Treatment of hepatitis C
in individuals on LA CR regimens may involve interac-
tions between cabotegravir and antivirals for hepatitis C,
which need to be studied.
Cabotegravir is highly bound to albumin with less than
1% free drug in circulation57 and is primarily eliminated
via the predominantly hepatic UGT (uridine 5′-diphospho-
glucurnosyltransferase) metabolism pathway (mainly
UGT1A1, with a contribution from UGT1A9).58 No
dose-adjustment appears to be required in mild to moder-
ate hepatic impairment.57 Two individuals receiving oral
cabotegravir in LATTE and LATTE-2 met stopping cri-
teria for liver disease considered possibly drug-related.24,25
Therefore, concern still stands regarding cabotegravir in
known severe pre-existing liver disease, viral hepatitis, or
those on concomitant medications.
Despite patients with severe renal impairment being
excluded from treatment studies, a phase I study showed
oral cabotegravir may be administered without dose
adjustment in severe renal impairment (creatinine clear-
ance<30 mL/min, not on renal replacement therapy).59
Cabotegravir is also considered to not affect cardiac repo-
larisation although studies have only been done in healthy
subjects receiving oral cabotegravir.60 Data are lacking on
the use of rilpivirine in severe renal or hepatic impairment
and manufacturers recommend it is used with caution.22
Drug–drug interactions (DDIs)
Known DDIs with oral rilpivirine include proton-pump inhi-
bitors (presumably not a concern in injectable therapy), dex-
amethasone, rifampicin, phenytoin and carbamazepine.22 In
vitro studies found cabotegravir interacts with organic ion
transporter (OAT) 1 or OAT3 substrates with a small therapeu-
tic window such as methotrexate;61 however, physiologically
based pharmacokinetic (PBPK) models suggest no dose
adjustment is required.62 Rifampicin has been demonstrated
to induce oral cabotegravir metabolism, signiﬁcantly decreas-
ing cabotegravir exposure, and this result is expected in
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injectable LA preparations as well.63,64 Rifampicin is a corner-
stone in anti-tuberculous (TB) therapy and therefore CRwould
currently be contraindicated in those requiring TB treatment.
This is a key issue where TB incidence is high and where
coinfection is frequent.
Data in females
Trial participants are predominantly male: LATTE and
LATTE 2 participants were 96% and 92% male, respec-
tively, and both studies excluded pregnant women.24 Phase
III studies have recruited more women: 22% in FLAIR
and 33% in ATLAS, although numbers are unlikely to be
sufﬁcient to determine any differences in response by
sex.28,29
Of 200 participants in the PrEP cabotegravir study
HPTN 077,37 66% were female. HPTN 077 showed no
difference in proportions completing the regimen, similar
numbers of AEs leading to discontinuation, and similar
frequency of ISRs between females and males. There were
some pharmacokinetic differences, with females, unlike
males, consistently achieving target trough concentrations,
and in tail-phase kinetics where it is anticipated that the
terminal decay rate is 50% slower in females. A healthy
volunteer study of LA rilpivirine has demonstrated that
females have lower peak rilpivirine concentrations in both
serum and genital ﬂuids.18 More data on the pharmacoki-
netics of injectable CR in females are needed from treat-
ment trials to address the knowledge gaps in dosing,
safety, efﬁcacy and tolerability.
There is no interaction between cabotegravir and levo-
norgestrel or ethinyl oestradiol-containing oral contracep-
tives in healthy adult women65 nor was a change in
cabotegravir concentrations detected with any form of
hormonal contraception in women in the HPTN 077
study.66 To date, we are not aware of any data on interac-
tions between LA CR and depot contraceptives.
There are no studies of LA CR in pregnant women.
Increased activity of UGT1A1 and UGT1A9 during preg-
nancy may lead to increased cabotegravir clearance,
although the effect on drug concentration is unclear.67
Considering other INSTIs, there are proven changes in
raltegravir pharmacokinetics in pregnancy prompting an
increase in the recommended dose compared to non-preg-
nant females;68 however, no dose adjustment is required
for dolutegravir. Raltegravir has been favored in interna-
tional pregnancy guidelines in women with high baseline
VL, requiring treatment intensiﬁcation, or presenting in
late pregnancy.69,70 There is some evidence that INSTIs
contribute to greater likelihood of achieving undetectable
HIV RNA at delivery.71,72
Concern regarding teratogenicity of dolutegravir has
prompted recommendations to avoid it for women consid-
ering conception and during the ﬁrst trimester.69,70 Given
the lack of safety data in pregnant women and the long t1/2
of LA therapy, it cannot be recommended in those situa-
tions at present.
Children and adolescents
There are restrictions on the use of INSTIs and rilpivirine in
the pediatric population due to lack of data. There is one in
silico PBPK dose prediction study that has provided dosing
recommendations of LA CR in children and adolescents
weighing 15–70 kg.73 No dose prediction studies have
been undertaken in children weighing less than 15 kg. A
pharmacokinetic and safety study of LA CR in virologically
suppressed adolescents aged 12–18, MOCHA, is currently
in progress.74 Of importance will be the acceptability of
frequent injections in this group. This is particularly perti-
nent in younger children, in whom future studies may be
required.
Role in low- and middle-income countries
(LMIC)
The vast majority of study sites in HIV treatment studies
of LA therapy are based in high-income countries (HIC) in
predominantly white populations. This leaves large knowl-
edge gaps of its efﬁcacy and safety in those of other ethnic
backgrounds. Drug interactions discussed earlier are
among the challenges in the rollout of LA CR in countries
with a high incidence of TB.
Determinants of drug acceptability and adherence vary
across the globe and in different patient populations.75–77
Factors such as beliefs about ART, stigma, social support
or depressive symptoms are important determinants of
adherence78 and strategies to address them should be rele-
vant to the local context. Where HIV is still highly stig-
matized, injectable therapy may allow PLWH more easily
to conceal treatments from others, reducing risk of inad-
vertent disclosure.
To date, health care professionals have delivered LA
ART.33 This will be a challenge in clinics with a large
number of PLWH where injectables will require more
clinical time and in services covering wide geographical
areas. Strategies involving decentralized services or non-
health care workers administering injections may help.
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Requirement of cold chain and storage at 2–8°C may also
affect LA CR distribution in these settings.79
Outstanding questions and future
work on cabotegravir/rilpivirine
While we now have 48-week data from the ﬁrst phase III
clinical trials, there are ongoing trials yet to report and
follow-up data on the FLAIR and ATLAS studies will give
valuable information on durability of the regimen and
resistance emerging on treatment. Key information will
come from the ATLAS-2M study, evaluating the efﬁcacy
of the q8w regimen, which may provide practical, eco-
nomic and tolerability beneﬁt over q4w.80 In addition, the
MOCHA study in adolescents has potential to provide data
for much-needed easier adherence74 and the phase III
study NCT03635788, enrolling participants with a history
of difﬁculty adhering to oral treatment regimens should
help deﬁne the role of IM LA therapy in this population.81
Importantly, there are outstanding knowledge gaps in the
use of injectable CR for HIV treatment in females and its
use in pregnancy cannot be recommended at present.
Real-world data will be essential in deﬁning the groups
of individuals most likely to beneﬁt from LA therapy; with
those with previous NNRTI resistance, those with frequent
non-attendance at the clinic and those with previous adher-
ence difﬁculties are key populations who may stand to
beneﬁt. Further data on the “tail” after a missed injection
and advice on how to manage this are needed as well as is
data on the safety of therapy without the oral lead-in.
Pharmacokinetics and drug interactions will be key
among those with OIs, or who develop OIs while on
therapy, since switching from LA regimens presents chal-
lenges. We await further data on whether the neuropsy-
chiatric SE of dolutegravir and the weight gain potentially
attributable to INSTIs are seen with cabotegravir.
In conclusion, we proceed with caution into this new
era of HIV therapy, which could lift the burden of daily
oral therapy for many people living with HIV, but which
must be supported by robust safety and durability data as
well as real-world cohorts.
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